Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Safety and Efficacy of Methylprednisolone Infiltration in Anserine Bursitis Treatment

This study has been completed.
Information provided by:
Universidad Autonoma de Nuevo Leon Identifier:
First received: July 28, 2010
Last updated: September 17, 2010
Last verified: June 2009
To investigate the safety and efficacy of methylprednisolone infiltration in anserine bursitis treatment

Condition Intervention Phase
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase 2 Double-blinded, Placebo-controlled, Clinical Trial for Safety and Efficacy of Methylprednisolone Infiltration in Anserine Bursitis Treatment

Resource links provided by NLM:

Further study details as provided by Universidad Autonoma de Nuevo Leon:

Primary Outcome Measures:
  • WOMAC score [ Time Frame: 4 weeks ]

    The WOMAC (Westren Ontario and McMaster Universities) index is used to assess patients with osteoarthritis of the hip or knee using 24 parameters. It can be used to monitor the course of the disease or to determine the effectiveness of anti-rheumatic medications.

    Pain, Stiffness and Physical functionVisual analogue scale (VAS) may be used ranging from 0 to 10.

Secondary Outcome Measures:
  • VAS satisfaction [ Time Frame: 4 weeks ]
    Visual Analoge Scale for satisfaction

  • Improvement [ Time Frame: 4 weeks ]
    Percentage of improvement

  • SAFETY [ Time Frame: 4 weeks ]
    Pain at infiltration site, ecchymosis, bleeding, paresthesias, skin infection, anaphilaxy, vasovagal reaction

Enrollment: 58
Study Start Date: September 2009
Study Completion Date: July 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Methylprednisolone
Infiltration of 40 mg of methylprednisolone acetate plus 1 mL of xylocaine
Infiltration of 40 mg of methylprednisolone acetate plus 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days
Placebo Comparator: Placebo
Infiltration of 1 mL of xylocaine
Infiltration of 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical diagnosis of anserine bursitis

Exclusion Criteria:

  • Intraarticular pathology that reflects pain in the medial part of the knee
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01205477

Hospital Universitario "José Eleuterio González"
Monterrey, Nuevo León, Mexico, 66024
Sponsors and Collaborators
Universidad Autonoma de Nuevo Leon
Study Director: Mario Alberto Garza Elizondo, MD Universidad Autónoma de Nuevo León
  More Information

Calvo-Alén J, Rua-Figueroa I, Erausquin C. Anserine bursitis treatment: local corticoesteroid injction against NSAID: a prospective study [Spanish]. Rev Esp Reumatol. 1993;20:13-15.

Responsible Party: David Vega Morales, Departamento de Reumatología, Hospital Universitario "José Eleuterio González" de la Universidad Autónoma de Nuevo León Identifier: NCT01205477     History of Changes
Other Study ID Numbers: RE09-009
Study First Received: July 28, 2010
Last Updated: September 17, 2010

Keywords provided by Universidad Autonoma de Nuevo Leon:
Anserine bursitis

Additional relevant MeSH terms:
Joint Diseases
Musculoskeletal Diseases
Prednisolone acetate
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Prednisolone hemisuccinate
Prednisolone phosphate
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Anti-Arrhythmia Agents
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents
Autonomic Agents
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Neuroprotective Agents processed this record on April 28, 2017